Aims We sought to determine the diagnostic performance, clinical profiles and outcomes of anomalous aortic origin of coronary ... echocardiographic windows: parasternal short/long axis and apical ...

Aortic valve ... the parasternal views and by the semiquantitative two-dimensional visual estimate method from different echocardiographic views. Left ventricular ejection fraction values were ...

For visualisation of the pulmonary valve, the parasternal short axis view and alternatively the anterior angulated ... is less likely to occur in pulmonary valve stenosis than in aortic stenosis, in ...

Background—Noninvasive assessment of functionally stenotic small-diameter aortic mechanical prostheses ... The internal diameter of the prosthetic valve ring was measured from 2-dimensional images in ...

Citation: Early transcatheter aortic valve replacement reduces cardiovascular events in asymptomatic aortic stenosis patients (2025, May 2) retrieved 24 May 2025 from https://medicalxpress.com ...

The Axis Short Duration Fund Growth has an AUM of 9640.47 crores & has delivered CAGR of 6.44% in the last 5 years. The fund has an exit load of 0.00% and an expense ratio of 0.89%. The minimum ...

As in the SMART trial, early hemodynamic differences have yet to result in a clinical impact—but it may just be a matter of ...

Get Instant Summarized Text (Gist) The FDA has approved the SAPIEN 3 TAVR platform for patients with severe asymptomatic aortic stenosis. In a median 3.8-year follow-up, TAVR reduced the combined ...

A transcatheter aortic valve replacement platform was approved for severe asymptomatic aortic stenosis. Edwards Lifesciences’ TAVR platform is the first to be approved in this population.

Asymptomatic patients with severe aortic stenosis can now undergo transcatheter aortic valve replacement, thanks to the US Food and Drug Administration’s approval of the new indication for the balloon ...

The Axis Ultra Short Duration Fund Direct Growth has an AUM of 6122.17 crores & has delivered CAGR of 6.28% in the last 5 years. The fund has an exit load of 0.00% and an expense ratio of 0.36%.